Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Charite University, Berlin, Germany
Prostate cancer is in Germany with approximately 25% of all cancers the most common cancer among man. Assumably there will be an increase in prostate cancer in the next few years because of demographic factors. The progressive metastatic prostate cancer often develops an androgen resistance. This so-called Castration-Resistant Prostate Cancer (CRPC) is not responsive to androgen deprivation therapy. Depending on symptoms and progression first-line chemotherapy - docetaxel and abiraterone are available.
Intermittent fasting as a form of caloric restriction has been studied most extensively experimentally in recent years. It showed consistent beneficial effects on relevant inflammatory and oncological pathways. In the field of preclinical oncology research groups have recently focused on intermittent fasting with chemotherapeutic treatment and promising experimental data have been published. In summary, the combination of fasting and chemotherapy was more effective in various cancer animal models than chemotherapy alone.
Age
25–89
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of CRPC or hormone-sensitive prostate cancer with high metastatic load
Cancer is treated to guidelines conventionally with chemotherapy or with a combination of hormone therapy and chemotherapy.
You may not be if
Underweight (BMI \<20 kg/m2) or actual weight decrease \>2 kg or \>5 kg in the last 1 or 3 months.
Eating disorder
Dementia
Psychosis
Terminal illness with a significant limitation of mobility and overall vitality
Diabetes mellitus type 1
Renal insufficiency stage \> 2, GFR \<60mlmin / 1.73 m2
Clareo Health | Fasting and Nutritional Therapy in Patients With Advanced Metastatic Prostate Cancer
